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Abstract: Tau protein, found in both neuronal and non-neuronal cells, forms aggregates in neurons
that constitutes one of the hallmarks of Alzheimer’s disease (AD). For nearly four decades, research
efforts have focused more on tau’s role in physiology and pathology in the context of the microtubules,
even though, for over three decades, tau has been localised in the nucleus and the nucleolus.
Its nuclear and nucleolar localisation had stimulated many questions regarding its role in these
compartments. Data from cell culture, mouse brain, and the human brain suggests that nuclear tau
could be essential for genome defense against cellular distress. However, its nature of translocation
to the nucleus, its nuclear conformation and interaction with the DNA and other nuclear proteins
highly suggest it could play multiple roles in the nucleus. To find efficient tau-based therapies, there
is a need to understand more about the functional relevance of the varied cellular distribution of tau,
identify whether specific tau transcripts or isoforms could predict tau’s localisation and function and
how they are altered in diseases like AD. Here, we explore the cellular distribution of tau, its nuclear
localisation and function and its possible involvement in neurodegeneration.
Keywords: tau; nucleus; nucleolus; Alzheimer’s disease; paired helical filament;
neurofibrillary tangles
1. Introduction
Tau (tubulin-associated unit) is a low molecular weight protein, first identified by Weingarten et al.
which showed the capacity to promote microtubule assembly in vitro [1]. It is expressed in higher
eukaryotes and found in both neuronal and non-neuronal cells, but predominating in neurons [2–5].
Besides its widely known role in microtubule assembly and stability, tau has become known for
many other functions, such as the maintenance of axonal transport and providing linkage for signal
transduction [5–8]. Tau is a product of the microtubule-associated protein (MAPT) gene, located
on chromosome 17q21.1 [9–11]. The tau gene, through complex post-transcriptional processing,
yields predominantly three transcripts: a less abundant 2kb tau transcript which encodes for a tau
mainly targetted to the nucleus [12]; 6kb transcript which encodes for tau predominantly directed
to the soma/axons in the central nervous system (CNS) [11,13]; and 8/9 kb transcript producing a
tau preferentially expressed in the retina and peripheral nervous system (PNS) and with apparent
molecular weight of about 110–120 kDa, often called high molecular weight (HMW) tau [14,15]. The
8/9 kb transcript arises from the inclusion of exon 4A from the tau gene during tau pre-mRNA
processing. The 2 kb and 6kb transcripts result from the same pre-mRNA polyadenylated on different
sites, with the 2 kb transcript having poly-A tail addition about 3.5 kb before that of the 6 kb transcript.
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This is responsible for the different preferential location of their products, and may impact on their
function and stability [15–18].
The tau gene has 16 exons, of which, exon 2, 3, 4A, 6, 8, 10 and 14 are alternatively spliced [10,11].
Theoretically, splicing of this gene could yield up to 30 different variants of tau protein, thus creating
an additional layer of complexity to the distribution of tau in different tissues [6,11,15,19,20]. The
alternate splicing of exon 2, 3 and 10 generates the six widely known isoforms of tau in the CNS,
ranging from 352 to 441 amino acids in length and 60–74 kDa in weight on SDS-PAGE (Figure 1) [5,6].
The smallest isoform is found in the foetal brain, expressing three microtubule-binding repeats on its
C-terminal (3R) and 0 N-terminal inserts, and is called foetal tau. The other five isoforms are bigger
and predominantly found in the adult brain, having either three or four (3R/4R) microtubule binding
repeats and the presence or absence of 1 or 2 N-terminal inserts [6].
Figure 1. Tau gene, protein isoforms, and structure. The tau gene has 16 exons; exon 1, 4, 5, 7, 9, 11, 12
and 13 (light blue) are constitutively transcribed in the CNS [5]. Exon 4A, 6 and 8 (orange) are rarely
expressed in the brain but included in mRNA of most peripheral tissues, while exon 14 forms part of
the 31 untranslated region of the tau mRNA [11,21]. Alternate splicing of exon 2 (blue), 3 (Green) and
10 (Yellow) in the CNS generates the widely known six isoforms of tau; 352–441 amino acids in length
and 60–74 kDa in weight on SDS-PAGE [5]. Depending on the inclusion and/or exclusion of exon 2, 3
and 10, tau can have three or four (3R/4R) microtubule binding repeats and the presence or absence of
1 or 2 N-terminal inserts, leading to the six widely known isoforms of tau in the CNS. Structurally, the
tau molecule is subdivided into four regions; an N-terminal acidic region; Proline-rich region/domain
(PRD), repeat domain region and a C-terminal region.
Structurally, tau is subdivided into four regions; an N-terminal acidic region; a Proline-rich domain
(PRD), repeat domain region and a C-terminal region, and the epitopes across these regions vary
depending on the tau isoform [5,6]. Isoform localisation preference also exists between developmental
stages, tissues, cell lines, brain regions and intracellular compartments [12,15,19,20,22]. For instance, in
the murine brain, the 0 N and 1 N tau predominate in the cell body/axons and nucleus, respectively [13];
and in SH-SY5Y neuroblastoma cells, high and low molecular weight tau both exist, and tau may
predominantly localise to the nucleus or cytoplasm depending on whether the cells are differentiated
or not [23].
It is thus clear that the complex posttranscriptional processing of the tau message yields numerous
isoforms with varying localisation. However, tau researchers have placed more focus on the tau
localised to the axons, likely due to its well-known role in microtubule stability and dynamics,
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axonal transport and involvement in the pathogenesis of many neurodegenerative diseases, such
as Alzheimer’s disease (AD). In AD, tau misfolds to form paired helical filaments (PHF) which are
deposited in neurofibrillary tangles (NFTs) [5], which together with amyloid plaques, are the principal
hallmarks of the disease as described by Alois Alzheimer’s in 1906 [24].
Electron microscopy reveals that PHFs (Figure 2b) are made up of a twisted ribbon-like
structure (Figure 2a), whereby two filament twist around one another [25]. Structurally, both tau
filaments from human brain and from in vitro assembly of recombinant tau protein have cross-β
structure [26]. However, the exact mechanism of tau assembly into PHFs is still not well understood.
Both hyperphosphorylation and truncation have been proposed as key molecular events in the
abnormal tau aggregation leading to the formation of PHFs. While much attention has focused
on hyperphosphorylation as a mechanism to induce the self-assembly of tau, an alternative is that tau
truncation is the trigger [27–30].
Figure 2. Transmission electron micrographs showing (a) paired helical filaments in human AD brain;
and (b) a neurofibrillary tangle, immunogold labelled with anti-tau antibody.
Many studies have proposed that tau phosphorylation is associated with tau assembly into
PHFs [27,28]. However, these studies have been based upon in vitro experiments and animal models,
and so it has been argued that further supporting evidence is required using human AD samples.
It has been shown that the core of PHFs contains truncated forms of tau protein [31]. Novak et al.
demonstrated that truncation is mediated by specific cleavage events in vivo [29,32]. Furthermore,
it has been suggested that truncated tau can serve as a nucleus for the assembly of endogenous tau
into neurofibrillary tangles [33]. To understand and gain more insight into the relationship between
phosphorylation and truncation, a more recent immunohistochemical study of AD brain tissue revealed
that truncated tau represents an early neurotoxic form and proposed that phosphorylation may play a
neuroprotective role by inhibition of tau aggregation [34].
Regardless of the mechanism involved in tau aggregation, many studies have revealed the
localisation of tau in multiple cellular compartments (discussed later). This has led to the suggestion
that tau is a multifunctional protein, as such; its involvement in neuronal physiology and pathology
needs to be regularly reviewed in light of new discoveries. Here, we discuss the unconventional
localisation and function of tau, especially, as it relates to the nucleus, and how it may play a role in
neurodegenerative diseases like AD.
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2. Nuclear Tau and Alzheimer’s Disease
2.1. Cellular Localisation of Tau
Tau is a cytosol-enriched protein, distributed within the somatodendritic compartment, but
predominating in the axons [35,36], that regulate microtubule assembly and stability, and axonal
transport of vesicles and organelles [7,37]. However, numerous studies have identified it in different
subcellular compartments. Its localisation to the microtubules of growth cones [38,39] and mitotic
spindle [40] has raised questions as to whether it has a non-microtubule polymerizing function,
since the microtubules in these two locations are more dynamic than axonal microtubules [41]. Tau,
mostly in a dephosphorylated state, has been localised in the plasma membrane of different cell
lines [42]. Its N-terminal domain mediates the interaction with the plasma membrane [6]. In rat cortical
neurons, a significant quantity of tau is localised to the membrane and this tau is dephosphorylated
at Tau-1, AT8 and PHF-1 epitopes [43]. This tau-membrane interaction is highly dynamic and
depends on phosphorylation, such that inhibiting Casein kinase 1 (CK1) or Glycogen synthase kinase 3β
(GSK3β) significantly increased tau translocation to the membrane, and mimicking tau N-terminal
phosphorylation prevented the tau-membrane localisation [43]. Tau has also been identified in the
lipid rafts of the Tg2576 mouse brain, the AD brain [44], and lipid rafts of primary neurons, where it is
regulated by Aβ oligomers [45]. In neurons, it localises in a good quantity within the synapses [46]. This
different localisation of tau provides evidence for its role in non-microtubule-associated functions, such
as signal transduction [6,41]. In support of this, Ittner et al. [8] showed that tau localised to the dendrites
mediates Aβ toxicity by targeting the sarcoma (Src) kinas FYN to post-synaptic NMDA receptors in
the mouse brain. Hyperphosphorylation of tau in AD models has also been shown to mislocalise tau to
the dendrites, where it alters synaptic function by affecting glutamate receptor trafficking [47]. These
studies collectively suggest that tau-associated factors that promote neurodegeneration, such as tau
phosphorylation, could change the localisation of tau and its functions, and trigger its somatodendritic
accumulation, axonal microtubule disassembly, PHF formation and neurodegeneration [48].
Apart from the compartments above, tau has been localised to the ribosomes of both neurons and
astrocytes in the AD brain [35,49]. Papasozomenos and Su also found abnormally phosphorylated tau
associated with purified ribosomes from AD brains but not from control brains [50]. Its association
with the ribosomes raised interesting questions on whether it plays any function related to protein
synthesis. To date, the functional relevance of this association is still elusive. In the human brain, tau
has also been found to partially colocalise with KDEL (a marker of the endoplasmic reticulum), and
Golgin 97 (a marker of Golgi apparatus), and that this colocolisation was more apparent in the AD
brain [51]. In the AD brain, tau also colocalised with the marker of the mitochondria (COX IV) [51].
Tang et al. [51] showed that cells engineered to have upregulated mTor activity also showed tau signals
with the endoplasmic reticulum, golgi, and the mitochondria, generally indicating that the enhanced
mTor activity caused the trafficking of tau and its subsequent release into the extracellular space. Aside
from these extra-nuclear locations of tau, it has been localised within the nucleus of the mouse brain
neurons [52,53], within the nucleus and nucleolus of different undifferentiated primate cell lines [3],
and the nucleus of the AD and control brain [50]. The evidence reviewed so far demonstrate that tau is
a ubiquitous protein, highly dynamic, with a broad range of potential functions and whose functions
and localisation are altered in neurodegenerative disease. Considering the importance of the nucleus
in cellular homeostasis, out of all the different localisations of tau, we are particularly interested in its
nuclear localisation as this raises many questions regarding its likely role in the nucleus, and how this
is influenced in tauopathies. Hence, this review focuses on nuclear tau and its potential nuclear roles
in physiology and pathology.
2.2. Nuclear Tau: Three Decades of Discovery
In 1988, Metuzals and coworkers published a paper demonstrating the presence of PHF profiles
within the nucleus of AD brain biopsies [54]. Around the same time, using immunofluorescence
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microscopy with Tau-1 antibody (which detects dephosphorylated tau), tau was localised within the
nucleus of CG human neuroblastoma cells, specifically at the nucleolar organiser region (NOR) of
the acrocentric chromosomes in dividing cells—the site of rRNA genes; and the fibrillar region of the
nucleolus in the interphase cells—the site of rRNA transcription [3]. Similar tau staining patterns were
found in other primate cell lines, but no tau immunoreactivity was observed in the non-primate cell
lines used in their study. This finding was further confirmed by the same group with immunoblotting
using the mAb Tau 46.1 [12], and sense and antisense transfection strategies [55] in neuroblastoma
cells. Similarly, the neuroblastoma LA-N-5 cell line also showed nucleolar tau localisation [56] and
Thurston et al. [57] revealed that other human non-neuronal cells like fibroblasts and lymphocytes
contain nucleolar tau. This discovery of nuclear tau was very significant, as it provided strong evidence
for a potential non-microtubule associated function for tau at that time. Accordingly, Lu and Wood [58]
showed that the microinjection of fluorescently-tagged bovine tau to cultured Chinese hamster ovary
(CHO) cells (which do not normally express tau protein) showed the accumulation of tau within both
the nucleolus and the centrosome. Cross et al. [59] colocalised tau with the centrosome of interphase
cells of the Huh-7 cells, SW-13 cells, and normal human fibroblasts. Using in vitro assays, they also
showed that the centrosomal tau promotes microtubule assembly at the centrosomes [59].
Subsequently, nuclear tau was localised in non-primate cell lines; such as the rat brain cell line
B103 [60], cultured mouse cortical neurons [52], and the mouse brain [13,53]. All this evidence makes a
strong case that tau is a bonafide nuclear protein, and also suggests that although nuclear tau could be
a shared phenomenon between different cell types of different species, some cells, especially primate
cells, show prominent nucleolar tau localisation [3,61,62]. Considering that nucleolar tau was found
predominantly in dividing cells, it was assumed that it functions only in dividing cells, such that its
expression ceases after differentiation [12]. However, the same group later identified nuclear tau in the
normal and AD brain with occasional scanty nucleolar staining [50]. The tau staining from their study
is mostly extranucleolar, prompting the authors to suggest that tau may have a nuclear function in
postmitotic neurons, and the absence of nucleolar tau may indicate its function is no longer necessary
in terminally differentiated cells. We were thus surprised and excited to localise nucleolar tau in
retinoic acid and brain-derived neurotrophic factor (BDNF) differentiated SHSY5Y cells [63]—a widely
used model for studying cellular changes associated with tauopathy. We used different antibodies
to confirm its localisation, and also colocalised it with various nucleolar proteins using both confocal
and immunogold transmission electron microscopy (manuscript in preparation). Using immunogold
labeling, we have also localised an appreciable amount of nucleolar tau in the normal and AD brain,
indicating that it is also a bonafide nucleolar protein (manuscript in preparation). The difficulty in
visualizing nucleolar tau in the work of Brady et al. [50] could be attributed to the processing protocol,
which affects the visualisation of tau [64].
We are still far from understanding the complete function of tau, especially as it relates its role
in the nucleus. This is partly complicated by the presence of many isoforms of tau in primate and
non-primate cells and the human brain. Indeed, the identity of nuclear tau, such as its posttranslational
modifications and the isoforms that exist within the nucleus is largely elusive. Post-translational
modifications of tau are important disease modifiers in tauopathies [5], and the ratio of the different
isoforms of tau also changes in some tauopathies [21]. To appreciate the role of nuclear tau in
physiology and pathology, there is the need to understand the real identity of the nuclear tau.
2.3. The Identity of Nuclear Tau
Alternate polyadenylation and alternative splicing could generate over 30 variants of tau. Most of
our knowledge has focused mainly on the 6 kb transcript of tau and the six widely known isoforms in
the central nervous system (CNS) (Figure 1). Whether nuclear tau is generated from a distinct transcript
and/or whether specific nuclear isoforms exist is not clear. It is possible that the tau that localises
to the microtubules is different from the one that localises to the nucleus. Otherwise, localisation of
tau with microtubule-binding message/function would render the microtubule undersupported and
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vulnerable. To begin to tackle this question, Liu et al. observed that 1N4R tau isoform in the murine
brain localises mainly to the nucleus, with some quantity in the soma, and dendrites, but not the
axons [13]. Interestingly, Wang et al. previously showed that the 2 kb tau transcript produces mainly
nuclear tau, with a small amount of cytosolic tau showing non-microtubule binding function [12].
Whether the murine brain also contains a 2 kb tau transcript is not known, but it would be interesting
to investigate if there is a special targeting at the transcript level that specifies the distribution of the
1N4R message to the nucleus. Other isoforms (e.g., 2N4R) and products of the 6 kb tau transcript can
also localise in small quantities within the nucleus [12,13]. Decoding the transcripts targeting and
isoform localisation of nuclear tau would enable a detailed understanding of tauopathies, some of
which arise from altered splicing and balance of tau isoforms [21].
Apart from the post-transcriptional processing that yields different tau transcripts and
isoforms, tau undergoes many post-translational modifications, such as phosphorylation [5]. Tau
phosphorylation has been suggested to be an important modifier of its function and the induction of
toxicity in neurons [43,65]. It is, therefore, important to investigate whether phosphorylated tau can
also localise to the nucleus and the functional relevance of this localisation. Indeed, Greenwood and
Johnson [56] found that nuclear tau in LAN-5 neuroblastoma cells may exist in both phosphorylated
and native state, to a similar extent to the tau pool in the cytoplasm. In vitro phosphorylation of
an intact isolated nucleus incubated with ATP Gamma 32P revealed that the nuclear tau is likely
not to be phosphorylated in the nucleus, but rather in the cytoplasm before translocation into the
nucleus. Other studies confirmed that a quantity of nuclear tau could exist in a phosphorylated state
in normal cell lines, mouse brain and the human brain [20,50,60,66]. However, some studies showed
that tau, especially nucleolar tau, can only be detected with Tau 1 antibody, which recognises tau
dephosphorylated at serine 195, 198, 199 and 202 [3,12,57]. Tau in the mouse brain also exists mainly
in a dephosphorylated state [64], especially under stress conditions [52]. Nuclear tau in the human
brain can also exist in a non-phosphorylated state [50]. Generally, these findings appear to suggest the
existence of both phosphorylated and dephosphorylated nuclear tau, which may vary depending on
cell type and intranuclear localisation, with the nucleolus restricted to mostly non-phosphorylated
tau. So far, it is not entirely clear what functional role is played by the nuclear phosphorylated and
non-phosphorylated tau. The nuclear compartment could also harbour an abnormal tau or tau on the
path of transformation to a pathological state. Using both Pr5 mice that express the P301L tau mutation,
and ∆Tau74, which express truncated form of wild-type human tau with no microtubule-binding
domain, Lu et al. showed that tau accumulates in the nucleus [64]. Further, the first paper that hinted
the localisation of tau to the nucleus, identified PHF strands within the AD brain nucleus [54]. Tau
rod-like deposits with ordered filamentous ultrastructure were also localised within the brain, in nuclei,
of subjects with AD and Huntington disease [67]. These finding collectively suggest a role for tau
within the nucleus in normal and disease conditions.
We generally have a modest understanding of the functional role of tau isoforms, but the work
of Wang et al. [12] and Liu et al. [13] strongly suggests that the bulk of nuclear tau may arise from a
distinct transcript and comprised of a dominant isoform. It is crucial to decipher whether this nuclear
tau typically interacts with and influences the DNA, and if/how this is important in pathology.
2.4. Capacity of Tau to Interact with the DNA
As far back as 1975, Bryan et al. showed that RNA could inhibit microtubule assembly in vitro,
through the reduction of the activity of a protein essential for tubulin assembly [68]. They showed
that tau protein could serve as this protein whose activity is reduced by the RNA. This provided
a preliminary evidence for interaction between tau and RNA. Indeed, two decades later, it was
further shown that RNA could induce the aggregation of tau into AD-like PHFs [69]. Considering the
relationship between the DNA and RNA, this finding also suggested a possible interaction between
tau and the DNA. Indeed, Corces et al. showed that brain depolymerised microtubule-associated
proteins bind the DNA with high affinity [70]. Using an in vitro assay, Corces et al. further showed
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that DNA inhibits microtubule assembly in a concentration-dependent manner, indicating that
microtubule-associated proteins have more affinity to the DNA than to the microtubules [71]. In
the study, they explicitly showed that tau protein-containing microtubule fractions bind the DNA.
Hua and He later found that addition of native tau to a solution of Calf Thymus DNA (CTDNA)
increased the melting temperature (Tm) of the DNA from 67 ˝C to 81 ˝C in a concentration-dependent
manner [72]. Similarly, tau protected pBluescript-II SK DNA from denaturation by raising its Tm from
75 ˝C to 85 ˝C. Kinetics study of tau and DNA further showed that tau can stabilise double-stranded
DNA [72]. This study made a strong case for tau as a DNA binding protein in vitro. However,
it is unclear whether the DNA interacts only with native tau or whether it can interact with tau
modified by posttranslational modifications, such as phosphorylation. Hence, the same group looked
at the interaction of phosphorylated or aggregated tau with the DNA. Using an in vitro approach,
they showed that tau phosphorylated by a neuronal cdc2-like kinase (NCLK) retains its ability to
bind the DNA and also increases the CTDNA melting Tm [72]. Interestingly, Hua and He observed
that when the conformation of tau is changed by aggregation, electrophoretic mobility shift assay
(EMSA) and agarose gel retardation assay both showed that phosphorylated and native tau lose
the ability to bind the DNA [72]. However, a recent study to further characterise the nature of this
interaction revealed strongly reduced or loss of capability of tau phosphorylated by GSK-3β for
binding and protecting the DNA against thermal denaturation [73]. Although both NCLK and GSK-3β
phosphorylate tau on multiple epitopes, including the PHF epitopes, GSK-3β can phosphorylate tau on
additional epitopes not phosphorylated by NCLK and has been suggested to play a dominant role in
tau phosphorylation [74]. Hence, this could be the reason for the discrepancy between the two studies
on phosphorylated tau-DNA interaction [73,75]. Using other approaches, other studies also showed
a similar reduction of the phosphorylated tau-DNA interactions [76,77]. Generally, these findings
revealed significant information about the interaction of tau with the DNA which will contribute
to understanding the role of nuclear tau in AD [5]. Based on these findings, it was postulated that
dysfunction in the phosphorylation of tau, such as in AD, might lead to its aggregation, thereby
affecting its ability to both stabilise the microtubule and protect the DNA [78]. In order to further
characterise the nature of the tau-DNA interaction, Hua et al. investigated the binding of tau to
double-stranded (dsDNA) or single-stranded (ssDNA) DNA, and the nature and flexibility of this
binding. Their results revealed that tau binds to dsDNA, but not ssDNA, and that this binding is
rapid, dynamic and reversible and occurs in a cooperative, rather than sequence-specific fashion [78].
It was suggested that the binding probably occurs via a charge effect since incubation of tau-DNA
solution in an increasing concentration of a high ionic strength buffer (NaCl) in the plasmid incubation
medium led to a NaCl concentration-dependent binding of tau to the DNA. Electron microscopy
showed that tau clustered around the DNA like a necklace. In contradiction to Hua et al. [78], a study
by Krylova et al. [79], using kinetic capillary electrophoresis (KCE), found that tau could not only bind
dsDNA, but it can also bind a ssDNA in sequence-specific fashion, and that it induces the denaturing of
dsDNA by binding to one of its strands sequence specifically. Hence, in an effort to clearly elucidate the
interaction of tau with the DNA and therefore understand the functional significance of this interaction,
Qu et al. using atomic force microscopy (AFM) showed that monomeric tau molecules bind the DNA at
a molar ratio of about 1:10 (tau/DNA), the equivalent to about 1 tau molecule to 700 bp of dsDNA [80].
Further studies revealed that tau binds and bends the DNA through AT-rich minor groove of the DNA,
likely through an electrostatic interaction with the ε-amino group of its lysine residues on its PRD
and microtubule binding domain (MBD); and that tau preferentially binds DNA sequences of about
13 bp or longer [81]. However, a recent study using nuclear magnetic resonance spectroscopy (NMR)
further revealed that this interaction may be through the second half of the PRD of tau (R209 to A246),
and a second interaction site on its MBD in the R2 repeat region (K267 to S289) [77]. The authors also
showed that tau interacts with not only AT-rich regions but GC-rich oligonucleotides, indicating a
general binding with the DNA backbone, independent of the bases, although hydrophobicity has
also been suggested to be essential in the tau-DNA interaction [76]. Therefore, there is sufficient
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evidence to indicate the capacity of tau to interact, stabilise and bend the DNA. However, most of these
experiments showing tau-DNA interaction were conducted outside a cellular environment, mostly
using recombinant proteins.
Greenwood and Johnson earlier found that out of the total tau in L-A-N-5 neuroblastoma cells,
14% are localised within chromatin fraction containing DNA, chromatin, and associated proteins [56].
This confirmed that tau could form a complex with the DNA within a cellular environment. Moreover,
they further showed that the tau in the chromatin fraction could exist in a phosphorylated state,
supporting the work of Hua and He which showed the capacity of phosphorylated tau to interact
with the DNA [75]. Using immunofluorescence microscopy, Sjoberg et al. provided evidence in situ
of tau-DNA interaction [62]. They showed that tau colocalised with diMeK9H3 and centromeric α
satellite DNA in human fibroblasts. They further showed that tau also binds to human α satellite
DNA sequences and murine γ-satellite DNA sequences. Rossi et al. also showed that tau localises
to the spindle poles and the mid-body in dividing cells [2]. Sultan et al. using immunoprecipitation
in primary neurons further showed that tau interacts in situ with the DNA [52]. Using netropsin—a
polyamide that binds the minor groove of dsDNA through AT-rich sequences; and methyl green—a
major groove binding drug—Sultan et al. confirmed that tau binds the minor groove of the DNA. All
these studies indicate that tau is a DNA-binding protein, so what is the functional role of nuclear tau?
2.5. Functional Role of Nuclear Tau
Tau’s localisation within the nucleus is particularly interesting, considering the importance of the
nucleus in cellular processes (Figure 3). Looking at cell lines and the human brain, nuclear tau exists in
different isoforms, with some cells showing diffuse nuclear staining of tau and some showing major
nucleolar tau signal [3,12,13,50,59,64]. While discussing the role of nuclear tau, it may be important
therefore to make a distinction between the nuclear tau ubiquitously distributed within the nucleus
and tau predominantly localised to the nucleolus. The difference in their nuclear distribution could
assign different roles for them in neuronal physiology and pathology. The localisation of tau to the
nucleolus in interphase cells or the NOR of dividing cells is very intriguing considering the role of
the nucleolus in cellular life [3,12,57]. The NOR contains ribosomal RNA (rRNA) genes and is the
source for the formation of the nucleolus [82]. The nucleoli play numerous cellular functions, the
prominent of which is rRNA synthesis, which gives rise to about 50% of total cellular RNA [83]. Within
the nucleolus, the rDNA transcription occurs at the border of the dense fibrillar component (DFC) and
fibrillar center (FC), while early processing of the nascent pre-rRNA transcript occurs in DFC [82]. Tau
localises to the DFC [62] and the ribosomes [35,49]. Tau may not play a role in nucleolar assembly
or formation [55], but together, these studies suggest it could be involved in rDNA transcription
and/or rRNA processing (Figure 3). The synthesis of ribosomes begins within the nucleolus, with
final maturation occurring in the cytoplasm. Hence, the localisation of tau both within the DFC of the
nucleolus and to the ribosomes probably indicates that it may play a role in the processing of ribosomes
from nascent pre-rRNA to maturation in the cytoplasm. Alternatively, nucleolar tau could play a part
in the heterochromatinization of rDNA [62]. The majority of rDNA are kept in a transcriptionally
inactive state through epigenetic mechanisms [84,85]. The silenced rRNA genes package to form a
nucleolar heterochromatin localised to a region adjacent to the perinucleolar heterochromatin [86].
Sjöberg et al. showed that tau interacts with the perinucleolar heterochromatin and α-satellite of
pericentromeric DNA [62]. This way, they proposed that tau could serve as a link between rDNA
repeats and pericentromeric heterochromatin, through which it could play a role in rRNA gene
silencing. Tau’s interaction with the perinucleolar heterochromatin makes it a potential regulator of
rDNA stability, especially against illicit recombination [85,86]. In dividing cells, its association with the
NOR of acrocentric chromosomes [3] also suggests a potential role for it in chromosomal stability [2]. Its
role in chromosomal stability supported by the observation that cells with tau mutations showed a high
degree of structural, numerical and stable chromosomal defects [2,87]. We are currently investigating
the role of nucleolar tau in neuronal cells, but in-depth studies in dividing interphase non-neuronal
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cells are also warranted to completely understand its role in peripheral tissues and how it is influenced
in diseases.
Figure 3. Potential functions of Nuclear tau. Tau has been shown to protect the DNA and RNA
from cellular distress [52,53]. It has been localised within the nucleolus, at the vicinity of the
rDNA and associated with a markers of the heterochromatin, within the nucleolus, it specifically
localises to the dense fibrillar component (DFC) of the nucleolus—a region involved with rDNA
transcription and processing of nascent pre-rRNA; collectively, this suggests a potential role for tau
in either rDNA heterochromatisation and stability, rDNA transcription and/or rRNA processing
and maturation [3,57,62]. Data from cell culture and human cells with varying tau mutations also
provides strong evidence for tau in the maitenance of chromosomal stability [2,87]. The nature of
interaction of tau-DNA interaction also suggests it could be be involved in nuclear transcriptional
regulation (See below for more detailed discussion). All these functions need further research to be
completely validated.
The capacity of tau to interact with nucleic acids, such as the RNA and DNA [68–71], and
raise the melting temperature of the DNA suggests it could also play a role in DNA protection [72]
(Figure 3). In vitro evidence showed that tau could protect the dsDNA from thermal denaturation and
enhance its renaturation [78]. Hydroxyl free radical (–OH) are known to induce dsDNA breakage.
In vitro evidence implicates tau in DNA protection from the –OH radical-induced DNA damage
in a concentration-dependent manner [73,78,81,88]. How this DNA protective role occurs is not
clear in vivo, especially because tau is mostly a cytosolic protein. It’s dynamic and reversible
nature of interaction with the DNA [78] suggests that it may shuttle between the cytosol and
the nucleus, similar to heat-shock proteins which shuttle between the cytoplasm and the nucleus
following heat-shock [89–91]. Like tau, some of these heat-shock proteins are enriched in both
cytoplasmic and nuclear compartments [92]. Heat-shock was previously shown to impact on tau
protein phosphorylation in male and female rats [93]. Papasozomenos also found widely distributed
tau immunoreactivity in the nucleus of an autopsy specimen of a subject with presenile dementia with
motor neuron disease, cited in [57]. These findings led Papasozomenos to postulate that tau may play
a role in stress response acting like heat-shock proteins (e.g., Hsp70) which upon heat shock translocate
into the nucleus and to the nucleolus to maintain the integrity of the nuclear and nucleolar DNA and
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then subsequently exit to the cytoplasm [89,91,94]. Hsp70, which is known also to translocate to the
nucleus upon heat shock, has been shown to protect the DNA [95]. In response to oxidative stress,
Hsp72 was also shown to translocate to the nucleus, where it interacts with many nuclear proteins,
including HMGB1, thus conferring cytoprotection by preventing the cytoplasmic translocation and
release of HMGB1 from the injured cells [96]. In a somewhat similar scenario, tau has been shown to
translocate to the nucleus following cellular distress to bind and protect the DNA in mouse primary
neurons [52]. The immunogold electron microscopy image from Sultan et al.’s study [52] also showed
dense nucleolar tau staining following the heat-stress, reminiscent of Hsp70 that translocates to the
nucleus and the nucleolus to protect nucleoplasmic and ribosomal DNA from DNA breaks [94]. Similar
to heat-shock proteins after the distress, Sultan et al. [52] showed that tau translocates back to the
cytoplasm. Protein dephosphorylation has been previously shown to be essential for the translocation
of Hsp70 into the nucleus in HeLa cells [90]. Interestingly, Sultan et al. showed that the nuclear tau
under heat stress is mainly dephosphorylated [52]. Although, tau knockout (KO) mice are viable and
show no apparent neuronal aberration [97], evidence from tau KO background also supports the DNA
protective role of tau. Sultan et al. [52] showed that tau KO cortical neurons are vulnerable to heat
stress-induced DNA damage while overexpression of hTau44 restored the DNA protective function of
tau in this cells. Using wild-type and tau KO mice, the same group further showed a role for tau in
RNA quality control and its reversible nuclear accumulation following cellular distress to protect the
DNA [53]. To date, the role for tau in DNA protection is the only functional role of nuclear tau that has
been clearly demonstrated both in vitro and in vivo. Generally, these findings and the similarities that
exist between tau and heat-shock proteins reinforces the idea that tau could be a heat-shock protein. In
our view, the tau that shuttles between the nucleus and the cytoplasm is a different isoform from the
tau mainly localised to the nucleolus in neuronal and non-neuronal cell lines [3,62].
Furthermore, from the various studies [52,81], some features of the tau-DNA interaction is
reminiscent of the interaction between chaperones and DNA [98]. An excellent example is that of
HMGB1—a DNA chaperone and an architectural minor groove binder that binds the DNA without
nucleotide sequence specificity. HMGB1 bends the DNA conformation and induces the formation of a
multi-protein complex [99]. It stabilises the structure of the nucleosome, serves as a transcriptional
facilitator and interacts with other minor groove binding proteins, such as TATA-binding protein
(TBP) [96,100,101]. Interestingly, similar to HMGB1, tau protein also acts like a DNA-chaperone
and architectural minor groove binder, as it binds the minor groove of DNA through its PRD and
MBD without nucleotide sequence specificity thereby twisting the DNA, as well as changing the
conformation of the DNA [52,80,102–104]. Tau also stabilises and prevents the denaturation of the
DNA [73,81,88]. The literature revealed that minor groove architectural proteins can unwind the DNA,
and also bend it so as to allow the formation of a multi-protein complex at the proximity of a specific
region of the DNA [99,105]. This complex is formed by the recruitment of transcriptional factors that
are bound at distantly separated DNA sites; in this way regulating gene expression [105]. Therefore,
the minor groove binders enhance the assembly, stability and activity of the multiprotein-DNA
complexes [99,105]. Previous studies also revealed that these proteins can stabilise the B-DNA
conformation, and might function to reverse a curvature at a specific DNA site to create a structure
that favours the recruitment of transcription factors. For instance, HMGI-Y was found to counteract on
the intrinsic DNA curvature that exist on its binding site within the interferon β (INF-β) enhancer, thus
allowing the recruitment of transcription factors by protein–protein interaction [106]. Furthermore, the
bending of the DNA induced by these proteins can alter the conformation of the DNA at a distant site
and thus affect the binding of other proteins at that site. And finally their nature of interaction with
the DNA could also allow transcriptional inhibition [99]. Hence, minor groove binding proteins could
have both transcriptional activation-like function and/or transcriptional inhibition-like function. They
may not be direct transcriptional regulators, but they may indirectly affect the chromatin conformation
and thus alter gene expression. This role has been well established for TATA-binding protein (TBP)
which binds the minor groove of the TATA element of the DNA, kinking it, and thus leading to the
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formation of pre-initiation complex (PIC), which constitutes RNA polymerase II and other initiation
factors (e.g., TFIIA) that alter transcriptional activity [105]. The formation of this multi-protein complex
is heterogeneous, as it often involves interaction between different minor groove binding proteins (e.g.,
HMGB1-TBP interaction) [100]. Therefore, based on the current data on the tau–DNA interaction, it
is not clear whether the primary function of tau is similar to that of the minor groove architectural
proteins that solely bend the DNA to initiate the formation of multi-protein complex, or whether tau
bends the DNA only as a way of protecting the DNA. Moreover, even though most transcription
factors bind the DNA with sequence specificity, and typically via the major groove [99], but some
also bind it without nucleotide sequence specificity, and such binding was proposed to be a way of
finding its specific binding site [107]. We wonder whether this could explain the discrepancy in the
literature where some studies showed that tau binds the DNA with sequence specificity [62,79], while
others [78] showed that it binds the DNA non-specifically? Tau could function as a transcriptional
regulator that first binds the DNA without sequence specificity, then later translocates to its correct
DNA interacting sequence. With all the characters mentioned above of minor groove binding proteins,
it appears attractive to speculate that tau protein being a minor groove binder could also function as
a transcriptional activator by unwinding the DNA conformation. Indeed, Krylova et al. had earlier
suggested that tau could be a transcriptional activator due to its ability to induce the separation of
dsDNA to ssDNA [79]. Padmaraju et al. also showed that tau can alter gene expression by causing a
change in DNA conformation from the standard B conformation to A–C conformations [103]. Qi et al.
also showed that tau could bind GC-rich oligonucleotides [77]. CpG islands are found in GC-rich
DNA regions and are essential regulators of transcription [108,109]. Some proteins with cytoplasmic
localisation, such as Msn2, have also been shown to undergo dephosphorylation following cellular
distress (e.g., Heat-shock) and translocate to the nucleus, where they function as a transcription
factor [110,111]. Evidence from Tau KO mice showed that tau could regulate the smarce1 gene, which
encodes for BAF57 [112]. In an analysis of ~11,000 mRNAs using microarray screening from wild-type
and tau KO mice, about 74 mRNAs were found to be significantly altered in the brain of 8-week-old
KO mice. Further analysis using Q-RT-PCR, showed a significant rise in 13 mRNA in the KO mice
brain [113]. These findings support a role for tau in nuclear gene regulation [97]. Therefore, a role for
tau in transcriptional regulation is something worth investigating.
Generally, the understanding of the functional role of nuclear and nucleolar tau is
preliminary; further studies are required in vivo to provide more details on tau’s nuclear role and
interacting partners.
2.6. Role of Nuclear Tau in Neurodegeneration
Tau protein is known to be involved in the pathogenesis of many neurodegenerative diseases,
especially due to its involvement in the regulation of neuronal microtubule and axonal transport.
Hyperphosphorylation of tau, its aggregation to PHF and NFTs in vulnerable neurons is a hallmark
of AD [5]. In AD, several reports indicate a reduction in NOR, rDNA transcription machinery and
product, decreased protein synthesis machinery and impaired protein synthesis [104,114–119]. Nuclear
tau has been localised in the AD brain, but compared to the control brain, no clear signature could be
established that could indicate its role in the disease. This is probably because only a few cases were
studied and variability could also exist due to the extent of pathology in the disease [50]. In AD, several
reports indicate a reduction in NOR or rDNA transcription [104,114,115]. Tau localises to the nucleolus
and NOR [3,12] and the ribosomes [35,49]. The nucleolar tau isNOR mainly dephosphorylated [3,12].
Upon phosphorylation, tau dissociates from the DNA [66]. If the nucleolar tau is involved in rRNA
biogenesis, hyperphosphorylation during AD could dissociate it from the nucleolus, and, as a result,
lead to altered ribosome biogenesis observed in AD. Interestingly, with the disease progression, a
recent study reported a significant decrease in nuclear tau from many regions of the hippocampus and
cortex, concomitant with significant aberration in the machinery regulating ribosome biogenesis,
such as upstream binding factor (UBF), nucleolin (NLC) and nucleophosmin (NMP1) in some
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regions of the AD brain [119]. However, if nucleolar tau is involved with heterochromatinization
of rDNA [62], it would remain unaltered or probably even more associated with the nucleolus,
to promote the heterochromatinization of rDNA genes, which can also lead to the reduction of
rDNA transcription. Indeed, the rDNA becomes hypermethylated in the mild cognitive impairment
(MCI) and AD brain [120]. However, the depletion of nuclear tau with AD progression reported
by Hernandez-Ortega et al. [119] does not appear to favour the later hypothesis. Moreover, the
methylation strength of the rDNA promoter can also vary between brain regions and stage of the
disease [120]. A detailed study is required to understand the role of tau in ribosome biogenesis, and for
this, the brain region and disease severity must be taken into account to have a clear picture of its role.
Rossi et al. showed that tau in non-neuronal cells carrying the P301L tau mutation consistently
present with a higher degree of structural, stable and numerical chromosome lesions, chromatin bridges
and decondensed chromosomes [2]. This finding was furthered confirmed in other non-neuronal cells
with varying tau mutations that rendered them more susceptible to genotoxic agents [87]. Considering
the localisation of tau to the chromosomes [2,3,12], its capacity to bind and protect the DNA in vitro
and in vivo [52,62,81] and the presence of different chromosomal aberrations and susceptibility to
genotoxic stress in cells carrying tau mutation, tau was suggested to be essential for the maintenance of
chromosome stability [87]. This suggests that the absence of normally functioning tau due to mutation
can affect tau’s role in genome protection and render cells susceptible to chromosomal instability.
Although tau’s potential role in chromosomal stability was demonstrated in non-neuronal cells [2,87],
it does not preclude the potential of tau in stabilising the chromosome of neurons. Also, tau mutations
do not cause AD, but nevertheless relationship exists between chromosomal instability and AD. For
instance, an aberration in the presenilin 1 (PS-1) gene has been shown to cause nondisjunction [121]. It
was further demonstrated that familial Alzheimer’s disease (FAD) mutant APP (V717F) transgenic
mouse and FAD-APP transfected cultured human cells, both produced chromosome missegregation
and aneuploidy in both brains and peripheral cells [122]. These authors also showed that Aβ can also
cause aneuploidy, including trisomy 21, in cultured cells. Interestingly, using spenocytes from tau
KO mice, they further showed the direct involvement of tau in this chromosomal aberration induced
by Aβ [122]. Increased level of aneuploidy specific to chromosome 21 has also been observed in the
cerebral cortex of the AD brain [123]. Considering the role of tau in chromosomal stability [2,87], these
studies could imply that in AD, increased production of Aβ could lead to tau aberration, such as
phosphorylation, preventing it from protecting the genome, as well as stabilizing the chromosomes.
Nuclear tau localises to chromosome 13, 14, 15, 21 and 22 [3]. Localisation of tau to these chromosomes
has been earlier proposed to provide a link between AD and Downs syndrome (DS) (Trisomy 21) [3].
People with DS that live beyond 30 years develop AD later in life [124]. The connection could arise due
to the overexpression of APP localised on chromosome 21, leading to increased Aβ production, which
promotes chromosomal aberration [122] and can cause cellular dysfunction through both cytosolic
and nuclear tau. Whether tau serves as the link between these two diseases and if aberration in tau
contributes to the chromosome 21 specific aneuploidy observed by Ivan et al. [123] in the AD brain is
something worth investigating.
It is also important to note that the involvement of nuclear tau in neurodegeneration could be
through the stress-induced inhibition of normal tau function through hyperphosphorylation and
aggregation [125]. Tau hyperphosphorylation and aggregation are among the principal modifications
considered essential for the development of PHF and NFTs [5]. Hyperphosphorylation of tau reduces
its nuclear translocation [126] and binding of tau to the DNA [76,77]. Aggregated tau also loses
its ability to bind the DNA [75]. Hence, oxidative stress-induced tau hyperphosphorylation and
aggregation could inhibit tau translocation to the nucleus and binding to protect the DNA [52,53,66,75].
However, this may not mean that phosphorylated tau completely becomes devoid of the nucleus.
As indicated in previous sections, several reports showed that nuclear tau could be found in a
phosphorylated state [2,50,56,66]. The existence of phosphorylated nuclear tau in normal cells is
hard to explain, but it has been shown to exist in many pathological scenarios. For instance, the
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infection of human neuroblastoma SK-N-MC cells with Herpes simplex virus type 1 (HSV-1) led to
the hyperphosphorylation and accumulation of tau in the nucleus [127]. Hyperphosphorylation of
tau co-occurs with DNA damage in formaldehyde-treated N2a cells, indicating an involvement of the
phosphorylated tau in DNA damage [73]. In vitro evidence suggests that phosphorylated tau can bind
and alter the conformation and the integrity of the DNA, and in this way, could change nucleosomal
organisation and impact on gene expression [103]. Indeed, recent findings from Drosophila melanogaster
model of tauopathy, mouse model and evidence from human AD brain tissue revealed a central
role of tau hyperphosphorylation in the induction of oxidative stress; DNA double-strand-breaks
(DSBs); decompaction of the heterochromatin; aberrant gene dysregulation, especially of genes
previously masked in the heterochromatin; cell cycle re-entry and neuronal apoptosis [65]. Although
the involvement of nuclear tau in the induction of these changes has not been investigated in this
study, tau phosphorylation was shown to be central to the induction of these pathogenic changes [65].
While writing this review, a new paper published by Hernandez-Ortega et al. [119] appears to provide
an attractive link to the role of tau in the neurodegenerative process. The paper showed the depletion
of nuclear tau in the neurons of the cornus ammonis 1 (CA1), dentate gyrus (DG), hilus, entorhinal
cortex (EC) and temporal neocortex with AD progression. Nuclear tau becomes almost entirely
depleted in NFT-bearing neurons of the CA1, EC and the temporal neocortex in later stages of the
disease. Interestingly, these changes were associated with a reduction in chromatin marks involved
with histone methylation (H3K9me3) and acetylation (H3k12ac) in the CA1 and DG neurons with
disease progression. This finding suggests that tau modifications due to the disease stress cause the
gradual depletion of tau from the nucleus even before NFTs formation and links this depletion to
chromatin modifications. Increase in CSF phosphor-tau helps to predict the progression to AD from
MCI [128]. Therefore, in AD, nuclear tau binding and protecting the DNA [52] or stabilizing the
heterochromatin [62]; could be altered due to the change in the tau molecule configuration, such as
phosphorylation, leading to its detachment from the DNA [73,77] and nuclear depletion [119], as a
result, causing the alteration of chromatin integrity [65,103] and aberrant gene regulation. Future
studies would provide a clear picture of the role of nuclear tau in neurodegeneration.
3. Conclusions
Since the discovery of tau in 1975, attention has focused largely on its microtubule-associated
function and dysfunction in diseases. It is now clear that tau is a multifunctional protein. Its localisation
to the nucleus in normal cells—phosphorylated and non-phosphorylated—is difficult to immediately
understand, but its interaction with the DNA to protect the genome mainly when dephosphorylated
supports the idea that aberrant modification in diseases like AD could alter its function and enhance
genome vulnerability and neurodegeneration. Importantly, considering its wide distribution in the
CNS and peripheral tissues, nuclear tau is potentially a global player for genome surveillance, in
particular against chromosomal aberrations. Its interaction with other nuclear proteins strongly
suggests it could play multiple roles in the nucleus, although further research is required to elucidate
this. Our understanding of nuclear tau remains lacking, and to find efficient tau-based therapies, there
is a need to understand more about the functional relevance of the varied cellular distribution of tau
and how it is altered in the disease state.
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